Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Recruiting 1No longer available 1Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5Myeloid 3Tumor-Agnostic 1Thoracic 1Sarcoma 1Gastrointestinal 1Dermatologic 1

Conditions

Sarcoma 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Colorectal Neoplasms 1

Interventions

Doxorubicin 25Cyclophosphamide 24pembrolizumab 20Specimen Handling 19Temozolomide 16Magnetic Resonance Spectroscopy 15Surgical Procedures, Operative 14Radiotherapy 13Blood Specimen Collection 13Biopsy 13atezolizumab 12Gemcitabine 12fludarabine 11Vincristine 11Ifosfamide 11X-Rays 8Trabectedin 8Nivolumab 8Irinotecan 8Imatinib Mesylate 8Drug Therapy 8cabozantinib 7Surveys and Questionnaires 7Radiation 7liposomal doxorubicin 5abemaciclib 5Sunitinib 5Standard of Care 5Radiation Dose Hypofractionation 5Dactinomycin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × avapritinib × Sarcoma × Clear all
NCT04771520 2026-03-02

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Recruiting
50 enrolled
DermatologicGastrointestinalSarcomaThoracic

Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡